title: Plasma type 1 collagen cross-linked C-telopeptide: a sensitive marker of acute effects of salmon calcitonin on bone resorption.
abstract: BACKGROUND
  The aim of the study was to determine the acute effects of salmon calcitonin (sCT) on bone resorption as assessed by plasma type 1 collagen cross-linked C-telopeptide (CTX). In addition, the plasma aminoterminal propeptide of type I procollagen (PINP) and osteocalcin (OC) were evaluated as markers of bone formation.
  
  
  METHODS
  In six healthy young women, after overnight fasting, single subcutaneous doses of 2, 10 and 50 IU as well as a nasal dose of 200 IU of sCT were administered consecutively with a 1-week washout period. During the control period, no drug was given. Blood samples were drawn at 0700 a.m. (baseline) and throughout the 9-h fasting period.
  
  
  RESULTS
  Both intranasal and subcutaneous sCT resulted in a significant reduction in plasma CTX by 50-60% as early as within 1 h. The plasma CTX showed a dose-dependent decrease over a dosage range of 2, 10 and 50 IU after subcutaneous administration of sCT. No significant difference was observed between the areas under curves (AUC) for plasma CTX following intranasal and subcutaneous administration of 200 and 2 IU of sCT, respectively. Synthesis of types I collagen remained unaffected by the dose of 50 IU of subcutaneously administered sCT when the acute effects were considered.
  
  
  CONCLUSIONS
  Plasma CTX is a sensitive marker in detecting acute changes of bone resorption after sCT administration.
authors.affiliation: Department of Internal Medicine 3, Faculty of Medicine, Charles University, U nemocnice 1, 12800 Prague, Czech Republic.
authors.forename: Vít
authors.initials: V
authors.lastname: Zikán
authors.forename: Jan J
authors.initials: JJ
authors.lastname: Stepan
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D015519:Bone Density / Q000187:drug effects; D001862:Bone Resorption / Q000188:drug therapy*; D002116:Calcitonin / Q000008:administration & dosage* / Q000494:pharmacology; D002118:Calcium / Q000097:blood; D003094:Collagen / Q000097:blood*; D024042:Collagen Type I; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D015675:Osteocalcin / Q000097:blood; D010281:Parathyroid Hormone / Q000097:blood; D010446:Peptide Fragments / Q000097:blood; D010455:Peptides / Q000097:blood*; D011347:Procollagen / Q000097:blood; D013997:Time Factors
chemical_list: D015415:Biomarkers; D024042:Collagen Type I; D010281:Parathyroid Hormone; D010446:Peptide Fragments; D010455:Peptides; D011347:Procollagen; C052929:collagen type I trimeric cross-linked peptide; C047202:procollagen Type I N-terminal peptide; D015675:Osteocalcin; C028815:salmon calcitonin; D002116:Calcitonin; D003094:Collagen; D002118:Calcium